1stOncology™: Cancer Intelligence Service – Page 14389 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

10-K/A [Amend] – Annual report [Section 13 and 15(d), not S-K Item 405]

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

NantKwest has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, NantKwest, 2018, MAR 12, 2018, View Source [SID1234524658]).

10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

Akebia has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Akebia, 2018, MAR 12, 2018, View Source [SID1234524657]).

10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

Aclaris Therapeutics has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Aclaris Therapeutics, 2018, MAR 12, 2018, View Source [SID1234524656]).

20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Hutchison China MediTech has filed a 20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 20-F, Hutchison China MediTech, 2018, MAR 12, 2018, View Source [SID1234524655]).